167 related articles for article (PubMed ID: 22019952)
1. Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.
Erdur FM; Soyoral YU; Emre H; Begenik H; Canbaz ET; Erkoc R
Clin Biochem; 2012 Jan; 45(1-2):162-4. PubMed ID: 22019952
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.
Soyoral YU; Canbaz ET; Erdur MF; Emre H; Begenik H; Erkoc R
J Pak Med Assoc; 2012 Aug; 62(8):849-51. PubMed ID: 23862266
[TBL] [Abstract][Full Text] [Related]
3. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
4. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.
Tahmaz M; Kumbasar B; Ergen K; Ure U; Karatemiz G; Kazancioglu R
Ren Fail; 2007; 29(7):927-30. PubMed ID: 17994463
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.
Unal A; Torun E; Sipahioglu MH; Tokgoz B; Kaya MG; Oymak O; Utas C
Intern Med; 2008; 47(11):1017-9. PubMed ID: 18520113
[TBL] [Abstract][Full Text] [Related]
6. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism.
Kursat S; Alici T; Colak HB
Clin Nephrol; 2005 Nov; 64(5):391-3. PubMed ID: 16312269
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
[TBL] [Abstract][Full Text] [Related]
9. Acute renal failure due to fenofibrate monotherapy.
Usküdar Cansu D; Yaşar NS; Korkmaz C
Anadolu Kardiyol Derg; 2011 Jun; 11(4):371-2. PubMed ID: 21592934
[No Abstract] [Full Text] [Related]
10. [Rhabdomyolysis induced by fenofibrate monotherapy].
Archambeaud-Mouveroux F; Lopez S; Combes C; Lassandre S; Amaniou M; Teissier MP; Galinat S
Rev Med Interne; 2006 Jul; 27(7):573-4. PubMed ID: 16716459
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.
Wang D; Wang Y
Medicine (Baltimore); 2018 Apr; 97(14):e0318. PubMed ID: 29620657
[TBL] [Abstract][Full Text] [Related]
12. A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.
Kiskac M; Zorlu M; Cakirca M; Karatoprak C; Peru C; Erkoc R; Yavuz E
Indian J Pharmacol; 2013; 45(3):305-6. PubMed ID: 23833382
[TBL] [Abstract][Full Text] [Related]
13. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report.
Suttels V; Florence E; Leys J; Vekemans M; Van den Ende J; Vlieghe E; Kenyon C
J Med Case Rep; 2015 Sep; 9():190. PubMed ID: 26347243
[TBL] [Abstract][Full Text] [Related]
14. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
Forcadell-Peris MJ; de Diego-Cabanes C
Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
[TBL] [Abstract][Full Text] [Related]
15. Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis--patient report and literature review.
Satarasinghe RL; Ramesh R; Riyaaz AA; Gunarathne PA; de Silva AP
Drug Metabol Drug Interact; 2007; 22(4):279-83. PubMed ID: 18447003
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.
Sousa AA; Kronit HS; Neves Fde A; Amato AA
Arq Bras Endocrinol Metabol; 2009 Apr; 53(3):383-6. PubMed ID: 19578603
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature.
Zhou J; Li D; Cheng Q
Medicine (Baltimore); 2020 May; 99(21):e20390. PubMed ID: 32481339
[TBL] [Abstract][Full Text] [Related]
18. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
19. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate: altered renal function.
Prescrire Int; 2011 Jun; 20(117):154-5. PubMed ID: 21682015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
